Valuation GlaxoSmithKline plc LIQUIDNET SYSTEMS

Stocks

Delayed LIQUIDNET SYSTEMS Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-0.40%	-

Jul. 10	GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial	AN
Jul. 10	GSK, Hansoh's targeted cancer drug hits main survival goal in China trial	RE

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	80,458	58,381	59,112	54,944	73,201	78,159	-	-
Change	-	-27.44%	1.25%	-7.05%	33.23%	6.77%	-	-
Enterprise Value (EV) ¹	100,296	75,578	74,152	68,039	87,654	93,446	90,382	87,200
Change	-	-24.65%	-1.89%	-8.24%	28.83%	6.61%	-3.28%	-3.52%
P/E	18.6x	3.93x	11.9x	21.3x	12.9x	12.4x	11.4x	11.3x
PBR	5.34x	5.47x	4.4x	4.02x	-	4.52x	3.78x	3.26x
PEG	-	0x	-0.2x	-0.4x	0x	1x	1.24x	11.05x
Capitalization / Revenue	2.36x	1.99x	1.95x	1.75x	2.24x	2.31x	2.19x	2.13x
EV / Revenue	2.94x	2.58x	2.45x	2.17x	2.68x	2.76x	2.54x	2.38x
EV / EBITDA	8.85x	7.23x	6.37x	6.36x	7.77x	8.06x	7.28x	6.89x
EV / EBIT	11.4x	9.27x	8.44x	7.44x	8.96x	9.13x	8.17x	7.61x
EV / FCF	22.6x	12.1x	13.6x	13x	13.7x	16.4x	14.8x	13.5x
FCF Yield	4.42%	8.28%	7.36%	7.67%	7.32%	6.1%	6.75%	7.41%
Dividend per Share ²	1	0.6125	0.58	0.61	0.66	0.6968	0.7336	0.7663
Rate of return	4.98%	4.26%	4%	4.53%	3.62%	3.55%	3.74%	3.91%
EPS ²	1.082	3.662	1.216	0.632	1.411	1.579	1.724	1.742
Distribution rate	92.4%	16.7%	47.7%	96.5%	46.8%	44.1%	42.5%	44%
Net sales ¹	34,114	29,324	30,328	31,376	32,667	33,881	35,610	36,707
EBITDA ¹	11,330	10,449	11,635	10,693	11,278	11,587	12,417	12,652
EBIT ¹	8,806	8,151	8,786	9,148	9,783	10,237	11,057	11,464
Net income ¹	4,385	14,956	4,928	2,575	5,716	6,523	7,044	6,974
Net Debt ¹	19,838	17,197	15,040	13,095	14,453	15,287	12,224	9,041
Reference price ²	20.08	14.38	14.50	13.46	18.24	19.62	19.62	19.62
Nbr of stocks (in thousands)	4,006,383	4,060,999	4,076,145	4,080,519	4,012,126	3,984,652	-	-
Announcement Date	2/9/22	2/1/23	1/31/24	2/5/25	2/4/26	-	-	-

¹GBP in Million²GBP

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	34.92x	12.63x	25.81x	0.57%	1,060B
JOHNSON & JOHNSON	27.42x	6.3x	17.1x	2.08%	619B
ABBVIE INC.	30x	7.34x	15.02x	2.76%	438B
ROCHE HOLDING AG	17.98x	4.45x	11.01x	2.97%	333B
NOVARTIS AG	21.52x	5.52x	13.36x	2.86%	282B
ASTRAZENECA PLC	21.56x	4.53x	12.65x	1.94%	267B
NOVO NORDISK A/S	14.17x	5.3x	10.9x	3.52%	218B
AMGEN INC.	23.77x	6.31x	11.12x	2.78%	196B
GILEAD SCIENCES, INC.	-46.02x	5.6x	31.12x	2.5%	161B
Average	16.15x	6.44x	16.46x	2.44%	397.1B
Weighted average by Cap.	23.86x	7.85x	18.16x	2%